02.16.07
Kendle
4Q Revenues: $86.4 million (+64)
4Q Loss: $1.8 million (earnings were $5.2 million in 4Q2005)
FY Revenues: $283.5 million (+40%)
FY Earnings: $20.0 million (+16%)
Comments: New business awards were $164 million in the quarter. For the year, total business authorizations, which consist of signed backlog and verbally awarded business, totaled a record $659 million. Loss in the quarter includes an $8.2 million impairment charge related to the August acquisition of the Phase II-IV clinical services business of Charles River Laboratories International, Inc.
4Q Revenues: $86.4 million (+64)
4Q Loss: $1.8 million (earnings were $5.2 million in 4Q2005)
FY Revenues: $283.5 million (+40%)
FY Earnings: $20.0 million (+16%)
Comments: New business awards were $164 million in the quarter. For the year, total business authorizations, which consist of signed backlog and verbally awarded business, totaled a record $659 million. Loss in the quarter includes an $8.2 million impairment charge related to the August acquisition of the Phase II-IV clinical services business of Charles River Laboratories International, Inc.